Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanistic study of mifamurtide in metastatic and/or recurrent osteosarcoma
ISRCTN82138287Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Sep 2014
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 2, randomised, open-label trial of mifamurtide and ifosfamide in osteosarcoma (OS) (3 arms), sponsored by University of Oxford. Primary endpoint: Objective radiological response at 36 weeks. Started Sep 2014; status: completed.
02
Drugs
mifamurtideifosfamide
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on ISRCTN82138287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN82138287.